Literature DB >> 29784593

Diagnosis and surgical management of inferior vena cava leiomyomatosis.

Chao Yang1, Huimin Fang2, Yunsong Yang2, Fei Cai2, Hong Zheng2, Bi Jin2, Yiqing Li2, Zheng Liu3, Mohamed A Zayed4.   

Abstract

OBJECTIVE: We aimed to review our experience in the diagnosis and surgical management of patients diagnosed with inferior vena cava leiomyomatosis (IVL).
METHODS: We retrospectively evaluated all patients diagnosed with IVL between 1999 and 2015. Patient demographics, diagnostic imaging, operative techniques, and perioperative outcomes were reviewed.
RESULTS: Over the study period, 16 patients with an IVL diagnosis were identified. In all patients, the diagnosis was made with ultrasound and magnetic resonance imaging. In 15 patients who underwent operative intervention, we observed three tumor extension routes from the uterus to the inferior vena cava: (i) via the internal iliac vein, (ii) via the ovarian vein, and (iii) via the anterior sacral vein. Complete tumor removal was achieved in all patients who underwent a one-stage operation (12 patients). Among these patients, antegrade tumor extraction from the right atrium was performed in nine patients, and retrograde extraction from iliac veins was performed in three. A two-stage operation with direct tumor transection and resection was necessary in a subset of patients to facilitate complete resection in one patient, and near-complete resection in two patients. Preoperative imaging and intraoperative findings demonstrated four distinct types of gross tumor morphologies: (i) type A solid cast (43.8%), (ii) type B hallow tube-like (12.5%), (iii) type C thread-like (18.7%), and (iv) type D mixed morphology (25%). Types A and B were the easiest tumor types to extract, and types C and D tumors were more difficult to remove given their fragility. Postoperative surgical pathology confirmed the diagnosis of IVL. All patients recovered successfully with no major complications; there were no deaths. One patient early in our experience had an incomplete resection and developed a recurrence that required re-intervention at 26 months from the initial operation.
CONCLUSIONS: IVL can be accurately diagnosed with ultrasound and magnetic resonance imaging. Surgical tumor resection with a one-stage operation can lead to reasonable outcomes and successful cure rates. The surgical plan can be tailored to the type of tumor morphology observed on preoperative imaging.
Copyright © 2018 Society for Vascular Surgery. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Inferior vena cava; Leiomyomatosis; Vascular tumor resection

Mesh:

Year:  2018        PMID: 29784593     DOI: 10.1016/j.jvsv.2018.03.013

Source DB:  PubMed          Journal:  J Vasc Surg Venous Lymphat Disord


  5 in total

1.  Management and prognosis comparison between incidental and nonincidental intravenous leiomyomatosis: a retrospective single-center real-life experience.

Authors:  Peipei Shi; Hongyang Xiao; Hua Li; Wenbin Tang; Aimin Ren; Li Ma; Ruiqin Tu; Sheng Yin; Jiarong Zhang
Journal:  Ann Transl Med       Date:  2022-05

2.  Intravenous leiomyomatosis: the first reported case of intraoperative intracaval embolisation of tumour to the right atrium.

Authors:  Gillian A Corbett; Catherine O'Gorman; Waseem Kamran
Journal:  BMJ Case Rep       Date:  2020-03-12

3.  Heterotopic Ossification of the Inferior Vena Cava Wall: A Case Report and Literature Review.

Authors:  Jihua Tian; Li Zhang; Min Hu; Xing Zeng; Yongjun Wang; Chunguang Yang; Zhiquan Hu
Journal:  Front Surg       Date:  2021-12-02

4.  Intravenous Leiomyomatosis Complicated by Arteriovenous Fistula: Case Series and Literature Review.

Authors:  Haoxuan Kan; Yang Cao; Yuexin Chen; Yuehong Zheng
Journal:  Front Cardiovasc Med       Date:  2022-06-13

5.  Intravenous Leiomyomatosis of the Uterus: A Retrospective Single-Center Study in 14 Cases.

Authors:  Qingbo Su; Xiquan Zhang; Hui Zhang; Yan Liu; Zhaoru Dong; Guangzhen Li; Xiangjiu Ding; Yang Liu; Jianjun Jiang
Journal:  Biomed Res Int       Date:  2020-02-14       Impact factor: 3.411

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.